Hyperbaric oxygen therapy in the treatment of osteonecrosis of the femoral head: A review of the current literature
Undersea and Hyperbaric Medicine, cilt.43, sa.3, ss.189-199, 2016 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 43 Sayı: 3
- Basım Tarihi: 2016
- Dergi Adı: Undersea and Hyperbaric Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.189-199
- Anahtar Kelimeler: avascular necrosis, femoral head, hip, hyperbaric oxygenation
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: To review the current literature on the use of hyperbaric oxygen (HBO2) therapy in the treatment of osteonecrosis of the femoral head (ONFH). Search strategy: We searched PubMed, Directory of Open Access Journals (DOAJ), EMBASE, Web of Science, Academic Search Complete, CINAHL and MEDLINE through April 2015. We hand-searched relevant textbooks, conference proceedings and the reference lists of review articles and clinical studies Study eligibility criteria: Randomized controlled trials (RCT) and observational studies (cohort study, case-control study, case series) that reported the outcome of patients who received HBO2 therapy for ONFH were included. Only English-language articles were included. Study quality was not used as an exclusion criterion. Study appraisal and synthesis methods: Two authors independently assessed trials for inclusion, extracted data and presented to other authors. Disagreements were resolved by consensus. Results: We identified eight clinical studies; two randomized controlled trials (RCTs); one historically controlled study; and five case series. The majority of the studies were small-scale, heterogeneous and methodologically weak. In four of the studies HBO2 therapy was combined with other treatment modalities, making it impossible to draw firm conclusions on the specific effects of HBO2 therapy. Hip survivorship in studies wherein HBO2 therapy was used alone was 95.5% in Steinberg Stage I lesions, 89% in Steinberg Stage II lesions and 100% in Ficat Stage II lesions. Conclusions: There is a room for HBO2 therapy in the management ONFH. Further RCTs, however, are required to better elucidate the role of HBO2 therapy in the treatment of ONFH.